[Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
D000328:Adult; D001714:Bipolar Disorder / Q000188:drug therapy*; D001921:Brain / Q000378:metabolism*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003863:Depression / Q000188:drug therapy*; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases
Consommation cérébrale et périphérique de L-dopa chez des patients atteints de syndromes parkinsoniens, dépressifs ou maniaques sous L-dopa en perfusion combinée ou non à un inhibiteur de la décarboxylase. Effets pharmacologiques.